MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma

Melanoma Research

Volumn 24, Issue 3, 2014, Pages 190-197

  Thunell, Lena K ^a   Bivik, Cecilia ^a   Wäster, Petra ^a   Fredrikson, Mats ^a   Stjernström, Annika ^a   Synnerstad, Ingrid ^a   Rosdahl, Inger ^a   Enerbäck, Charlotta ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

dysplastic nevi; hereditary melanoma; MDM2; MDM4; p53; superficial spreading melanoma

Indexed keywords

GENOMIC DNA; PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DYSPLASTIC NEVUS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEREDITARY MALIGNANT MELANOMA; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC MALIGNANT MELANOMA; WILD TYPE; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; HEREDITY; HETEROZYGOTE; MIDDLE AGED; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SKIN TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899957701     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000063     Document Type: Article

References (39)

1. Perry ME. The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol 2010; 2:a000968.
2. Box NF, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 2008; 21:525-533.
3. Zeron-Medina J, Wang X, Repapi E, Campbell MR, Su D, Castro-Giner F, et al. A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell 2013; 155:410-422.
4. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006; 25:1602-1611.
5. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-365.
6. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer 2007; 96:196-200.
7. Gwosdz C, Scheckenbach K, Lieven O, Reifenberger J, Knopf A, Bier H, et al. Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer 2006; 118:577-582.
8. Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, et al. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 2003; 121:1510-1514.
9. Stefanaki I, Stratigos AJ, Dimisianos G, Nikolaou V, Papadopoulos O, Polydorou D, et al. p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Br J Dermatol 2007; 156:357-362.
10. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
11. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006; 98:285-288.
12. Firoz EF, Warycha M, Zakrzewski J, Pollens D, Wang G, Shapiro R, et al. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res 2009; 15:2573-2580.
13. Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, et al. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. J Invest Dermatol 2012; 132:1471-1478.
14. Nan H, Qureshi AA, Hunter DJ, Han J. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control 2009; 20:171-179.
15. Kulkarni DA, Vazquez A, Haffty BG, Bandera EV, Hu W, Sun YY, et al. A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis 2009; 30:1910-1915.
16. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, et al. Singlenucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res 2010; 16:5244-5251.
17. Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 2006; 6:657-670.
18. Spica T, Fargnoli MC, Hetet G, Bertrand G, Formicone F, Descamps V, et al. EDNRB gene variants and melanoma risk in two southern European populations. Clin Exp Dermatol 2011; 36:782-787.
19. NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 1992; 268:1314-1319.
20. Hansson J, Bergenmar M, Hofer PA, Lundell G, Mansson-Brahme E, Ringborg U, et al. Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. J Clin Oncol 2007; 25:2819-2824.
21. Augustsson A, Stierner U, Suurkula M, Rosdahl I. Prevalence of common and dysplastic naevi in a Swedish population. Br J Dermatol 1991; 124:152-156.
22. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124:869-871.
23. Synnerstad I, Nilsson L, Fredrikson M, Rosdahl I. Frequency and distribution pattern of melanocytic naevi in Swedish 8-9-year-old children. Acta Derm Venereol 2004; 84:271-276.
24. Lang A, Palmeback Wegman P, Wingren S. The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol Rep 2009; 22:575-579.
25. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001; 61:7642-7646.
26. Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, McKee PH, Chin L, et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006; 45:447-454.
27. Capasso M, Ayala F, Avvisati RA, Russo R, Gambale A, Mozzillo N, et al. MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness. J Hum Genet 2010; 55:518-524.
28. Gluck I, Simon AJ, Catane R, Pfeffer R, Schachter J, Rechavi G, et al. Germline analysis of thymidine/guanidine polymorphism at position 309 of the Mdm2 promoter in malignant melanoma patients. Melanoma Res 2009; 19:199-202.
29. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007; 26:1317-1323.
30. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66:5104-5110.
31. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 2006; 43:950-952.
32. Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions.'The B-K mole syndrome'. Arch Dermatol 1978; 114:732-738.
33. Miller CT, Beleza S, Pollen AA, Schluter D, Kittles RA, Shriver MD, et al. cis- Regulatory changes in Kit ligand expression and parallel evolution of pigmentation in sticklebacks and humans. Cell 2007; 131:1179-1189.
34. Sjalander A, Birgander R, Kivela A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995; 45:144-149.
35. Li C, Chen K, Liu Z,Wang LE, Gershenwald JE, Lee JE, et al. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14 > A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol 2008; 128:1585-1588.
36. Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Magnusson KP, et al. Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet 2007; 39:1443-1452.
37. Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, Bertorelle R, et al. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci USA 2009; 106: 10236-10241.
38. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007; 39:1476-1482.
39. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999; 59:6091-6096.